Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer

References

• O’Connor MJ. Targeting the DNA Damage Response in Cancer. Mol Cell. 2015;60(4):547–560.
   PubMed Web of Science ®Google Scholar
• Chatterjee N, Walker GC. Mechanisms of DNA damage, repair, and mutagenesis. Environ Mol Mutagen. 2017;58(5):235–263.
   PubMed Web of Science ®Google Scholar
• Schreiber V, Dantzer F, Ame JC, et al. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol. 2006;7(7):517–528.
   PubMed Web of Science ®Google Scholar
• Hassa PO, Hottiger MO. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci. 2008;13:3046–3082.
   PubMed Web of Science ®Google Scholar
• Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol. 2015;33(12):1397–1406.
   PubMed Web of Science ®Google Scholar
• Sousa FG, Matuo R, Soares DG, et al. PARPs and the DNA damage response. Carcinogenesis. 2012;33(8):1433–1440.
   PubMed Web of Science ®Google Scholar
• De Vos M, Schreiber V, Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol. 2012;84(2):137–146.
   PubMed Web of Science ®Google Scholar
• Dulaney C, Marcrom S, Stanley J, et al. Poly(ADP-ribose) polymerase activity and inhibition in cancer. Semin Cell Dev Biol. 2017;63:144–153.
   PubMed Web of Science ®Google Scholar
• Langelier MF, Planck JL, Roy S, et al. Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science. 2012;336(6082):728–732.
   PubMed Web of Science ®Google Scholar
• Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med. 2015 Aug 13;13: 188.
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152–1158.
   PubMed Web of Science ®Google Scholar
• Langelier M-F, Pascal JMPARP. PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis. Curr Opin Struct Biol. 2013;23(1):134–143.
   PubMed Web of Science ®Google Scholar
• Maya-Mendoza A, Moudry P, Merchut-Maya JM, et al. High speed of fork progression induces DNA replication stress and genomic instability. Nature. 2018;559(7713):279–284.
   PubMed Web of Science ®Google Scholar
• Sugimura K, Takebayashi S, Taguchi H, et al. 1 ensures regulation of replication fork progression by homologous recombination on damaged DNA. J Cell Biol. 2008;183(7):1203–1212.
   PubMed Web of Science ®Google Scholar
• Zandarashvili L, Langelier M-F, Velagapudi UK, et al. Structural basis for allosteric PARP-1 retention on DNA breaks. Science. 2020;368(6486):eaax6367.
   PubMed Web of Science ®Google Scholar
• Zhou P, Wang J, Mishail D, et al. Recent advancements in PARP inhibitors-based targeted cancer therapy. Precis Clin Med. 2020;3(3):187–201.
   PubMedGoogle Scholar
• Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011;5(4):387–393.
   PubMed Web of Science ®Google Scholar
• Couch F, Hu C, Lilyquist J, et al. Abstract S2-01: breast cancer risks associated with mutations in cancer predisposition genes identified by clinical genetic testing of 60,000 breast cancer patients. Cancer Res. 2017;77(4 Supplement):S2-01-S02–01.
   PubMed Web of Science ®Google Scholar
• Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375(22):2154–2164.
   PubMed Web of Science ®Google Scholar
• Tung NM, Robson ME, Ventz S, et al. TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded). J Clin Oncol. 2020;38(15_suppl):1002.
   Web of Science ®Google Scholar
• Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–1961.
   PubMed Web of Science ®Google Scholar
• Bono JSD, Hussain M, Thiery-Vuillemin A, et al. PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration. J Clin Oncol. 2017;35(15_suppl):TPS5091–TPS5091.
   Web of Science ®Google Scholar
• Thomas A, Murai J, Pommier Y. The evolving landscape of predictive biomarkers of response to PARP inhibitors. J Clin Invest. 2018;128(5):1727–1730.
   PubMed Web of Science ®Google Scholar
• Nik-Zainal S, Davies H, Staaf J, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534(7605):47–54.
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421.
   PubMed Web of Science ®Google Scholar
• Polak P, Kim J, Braunstein LZ, et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet. 2017;49(10):1476–1486.
   PubMed Web of Science ®Google Scholar
• Birkbak NJ, Wang ZC, Kim JY, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012;2(4):366–375.
   PubMed Web of Science ®Google Scholar
• Timms K, Abkevich V, Neff C, et al. Abstract P6-05-10: association between BRCA1/2 status and DNA-based assays for homologous recombination deficiency in breast cancer. Cancer Res. 2013;73(24 Supplement):P6-05-10-P06-05–10.
   Google Scholar
• Popova T, Manié E, Rieunier G, et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 2012;72(21):5454–5462.
   PubMed Web of Science ®Google Scholar
• Birkbak NJ, Kochupurakkal B, Izarzugaza JM, et al. Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. PLoS One. 2013;8(11):e80023.
   PubMed Web of Science ®Google Scholar
• Loveday C, Turnbull C, Ramsay E, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet. 2011;43(9):879–882.
   PubMed Web of Science ®Google Scholar
• Gilardini Montani MS, Prodosmo A, Stagni V, et al. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. J Exp Clin Cancer Res. 2013;32(1):95.
   PubMed Web of Science ®Google Scholar
• Lloyd RL, Wijnhoven PWG, Ramos-Montoya A, et al. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene. 2020;39(25):4869–4883.
   PubMed Web of Science ®Google Scholar
• McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109–8115.
   PubMed Web of Science ®Google Scholar
• Brandsma I, Fleuren EDG, Williamson CT, et al. Directing the use of DDR kinase inhibitors in cancer treatment. Expert Opin Investig Drugs. 2017;26(12):1341–1355.
   PubMed Web of Science ®Google Scholar
• Tassone P, Tagliaferri P, Perricelli A, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 2003;88(8):1285–1291.
   PubMed Web of Science ®Google Scholar
• Byrski T, Dent R, Blecharz P, et al. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res. 2012;14(4):R110.
   PubMed Web of Science ®Google Scholar
• Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018;24(5):628–637.
   PubMed Web of Science ®Google Scholar
• Calabrese CR, Batey MA, Thomas HD, et al. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003;9(7):2711–2718.
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–917.
   PubMed Web of Science ®Google Scholar
• Turner NC, Telli ML, Rugo HS, et al. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <em>BRCA1/2</em> Mutations (ABRAZO). Clin Cancer Res. 2019;25(9):2717.
   PubMed Web of Science ®Google Scholar
• Menear KA, Adcock C, Boulter R, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008;51(20):6581–6591.
   PubMed Web of Science ®Google Scholar
• Shen Y, Rehman FL, Feng Y, et al. BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency. Clin Cancer Res. 2013;19(18):5003.
   PubMed Web of Science ®Google Scholar
• Wang L, Mason KA, Ang KK, et al. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs. 2012;30(6):2113–2120.
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–134.
   PubMed Web of Science ®Google Scholar
• Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235–244.
   PubMed Web of Science ®Google Scholar
• Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244–250.
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852–861.
   PubMed Web of Science ®Google Scholar
• Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377(6):523–533.
   PubMed Web of Science ®Google Scholar
• Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558–566.
   PubMed Web of Science ®Google Scholar
• Tung NM, Robson ME, Ventz S, et al. TBCRC 048: phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J Clin Oncol. 2020;38:4274-4282.
   Web of Science ®Google Scholar
• Dent RA, Lindeman GJ, Clemons M, et al. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res. 2013;15(5):R88.
   PubMed Web of Science ®Google Scholar
• Domchek SM, Postel-Vinay S, Im SA, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21(9):1155–1164.
   PubMed Web of Science ®Google Scholar
• Chan N, Bristow RG. “Contextual” synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clin Cancer Res. 2010;16(18):4553–4560.
   PubMed Web of Science ®Google Scholar
• Hegan DC, Lu Y, Stachelek GC, et al. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci U S A. 2010;107(5):2201–2206.
   PubMed Web of Science ®Google Scholar
• Dean E, Middleton MR, Pwint T, et al. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer. 2012;106(3):468–474.
   PubMed Web of Science ®Google Scholar
• Hafez N, Soliman HH, Fu S, et al. Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors. J Clin Oncol. 2020;38(15_suppl):1077.
   Web of Science ®Google Scholar
• Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495–2505.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019;381(25):2416–2428.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–1284.
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852–861.
   PubMed Web of Science ®Google Scholar
• Domchek SM, Aghajanian C, Shapira-Frommer R, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2016;140(2):199–203.
   PubMed Web of Science ®Google Scholar
• Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381(4):317–327.
   PubMed Web of Science ®Google Scholar
• de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382(22):2091–2102.
   PubMed Web of Science ®Google Scholar
• Murai J, Huang SY, Renaud A, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2014;13(2):433–443.
   PubMed Web of Science ®Google Scholar
• de Bono J, Ramanathan RK, Mina L, et al. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discov. 2017;7(6):620–629.
   PubMed Web of Science ®Google Scholar
• Turner NC, Telli ML, Rugo HS, et al. A Phase II Study of Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clin Cancer Res. 2018;2018(clincanres):1891.
   Google Scholar
• Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018;379(8):753–763.
   PubMed Web of Science ®Google Scholar
• Litton JK, Hurvitz SA, Mina LA, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31(11):1526-1535.
   PubMed Web of Science ®Google Scholar
• Ettl J, Quek RGW, Lee KH, et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol. 2018;29(9):1939–1947.
   PubMed Web of Science ®Google Scholar
• Drew Y, Ledermann J, Hall G, et al. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer. 2016;114(7):723–730.
   PubMed Web of Science ®Google Scholar
• Anne Patsouris OT, Nenciu D, Tran-Dien A, et al. RUBY: A phase II study testing rucaparib in germline (g) BRCA wild-type patients presenting metastatic breast cancer (mBC) with homologous recombination deficiency (HRD). J Clin Oncol. 2019 May 26;37 (15):1092-1092.
   Web of Science ®Google Scholar
• Wilson RH, Evans TJ, Middleton MR, et al. A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. Br J Cancer. 2017;116(7):884–892.
   PubMed Web of Science ®Google Scholar
• Oza AM, Tinker AV, Oaknin A, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017;147(2):267–275.
   PubMed Web of Science ®Google Scholar
• Abida W, Campbell D, Patnaik A, et al. Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): updated analyses. Ann Oncol. 2019;30:v327–v328.
   Google Scholar
• Sandhu SK, Schelman WR, Wilding G, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882–892.
   PubMed Web of Science ®Google Scholar
• Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA Oncol. 2019;5(8):1132–1140.
   PubMed Web of Science ®Google Scholar
• González-Martín A, Pothuri B, Vergote I, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381(25):2391–2402.
   PubMed Web of Science ®Google Scholar
• Moore KN, Secord AA, Geller MA, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):636–648.
   PubMed Web of Science ®Google Scholar
• Kopetz S, Mita MM, Mok I, et al. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. J Clin Oncol. 2008;26(15_suppl):3577.
   Web of Science ®Google Scholar
• Mahany JJ, Lewis N, Heath EI, et al. A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors. J Clin Oncol. 2008;26(15_suppl):3579.
   Web of Science ®Google Scholar
• Anders C, Deal AM, Abramson V, et al. TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Res Treat. 2014;146(3):557–566.
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364(3):205–214.
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J, Schwartzberg L, Danso MA, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2014;32(34):3840–3847.
   PubMed Web of Science ®Google Scholar
• Liu X, Shi Y, Maag DX, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res. 2012;18(2):510–523.
   PubMed Web of Science ®Google Scholar
• Chuang HC, Kapuriya N, Kulp SK, et al. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat. 2012;134(2):649–659.
   PubMed Web of Science ®Google Scholar
• Patel AG, De Lorenzo SB, Flatten KS, et al. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res. 2012;18(6):1655–1662.
   PubMed Web of Science ®Google Scholar
• Mateo J, Ong M, Tan DSP, et al. Appraising iniparib, the PARP inhibitor that never was—what must we learn? Nat Rev Clin Oncol. 2013;10(12):688–696.
   PubMed Web of Science ®Google Scholar
• Han HS, Diéras V, Robson M, et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Ann Oncol. 2018;29(1):154–161.
   PubMed Web of Science ®Google Scholar
• Puhalla S, Beumer JH, Pahuja S, et al. Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt). J Clin Oncol. 2014;32(15_suppl):2570.
   PubMed Web of Science ®Google Scholar
• Sato K, Akimoto K. Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive Breast Cancer. Clin Breast Cancer. 2017;17(3):e135–e142.
   PubMedGoogle Scholar
• Pothuri B, Brodsky AL, Sparano JA, et al. Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up. Cancer Chemother Pharmacol. 2020;85(4):741–751.
   PubMed Web of Science ®Google Scholar
• Isakoff S, Overmoyer B, Tung N, et al. P3-16-05: A Phase II Trial Expansion Cohort of the PARP Inhibitor Veliparib (ABT888) and Temozolomide in BRCA1/2 Associated Metastatic Breast Cancer. Cancer Res. 2011;71(24 Supplement):P3-16-05-P13-16–05.
   Google Scholar
• LoRusso PM, Tolaney SM, Wong S, et al. Abstract CT325: combination of the PARP inhibitor veliparib (ABT888) with irinotecan in patients with triple negative breast cancer: preliminary activity and signature of response. Cancer Res. 2015;75(15 Supplement):CT325–CT325.
   Google Scholar
• Turk AA, Wisinski KB. PARP inhibitors in breast cancer: bringing synthetic lethality to the bedside. Cancer. 2018;124(12):2498–2506.
   PubMed Web of Science ®Google Scholar
• Rodler ET, Kurland BF, Griffin M, et al. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer. Clin Cancer Res. 2016;22(12):2855–2864.
   PubMed Web of Science ®Google Scholar
• Sharma P, Rodler E, Barlow WE, et al. Results of a phase II randomized trial of cisplatin ± veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416). J Clin Oncol. 2020;38(15_suppl):1001.
   Google Scholar
• Dieras HSH VC, Kaufman B, Wildiers H, et al. Phase 3 study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer. Annals of Oncol. 2019 Sep 29;30 (suppl-5):v851-v934.
   Google Scholar
• Puhalla SL, Dieras V, Arun B, et al. Veliparib (V) monotherapy after progression on placebo (PL) + carboplatin/paclitaxel (CP) in patients with advanced HER2-negative g BRCA -associated breast cancer: crossover outcomes and exploratory biomarker analyses in BROCADE3. J Clin Oncol. 2020;38(15_suppl):1097.
   Web of Science ®Google Scholar
• HSH LP, Yau C, Denise Wolf AM, et al. Jo Chien, Rita Mukhtar, Anthony Elias, Borges Virginia, Rita Nanda, Douglas Yee, Kevin Kalinsky, Kathy S. Albain, Aixa Soyano Muller, Kathleen Kemmer, Amy S. Clark, Claudine Isaacs, Alexandra Thomas, Nola Hylton, W. Fraser Symmans, Jane Perlmutter, Michelle Melisko, Hope S. Rugo, Richard Schwab, Amy Wilson, Amy Wilson, Ruby Singhrao, Smita Asare, Laura J. Van’t Veer, Angela M. DeMichele, Ashish Sanil, Donald A. Berry, Laura J. Esserman, Trial Consortium I-SPY 2. CT011 - Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: results from the I-SPY 2 TRIAL. [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT011.
   Google Scholar
• Fasching PA, Jackisch C, Rhiem K, et al. GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD). J Clin Oncol. 2019;37(15_suppl):506.
   Web of Science ®Google Scholar
• CT011 - Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
   Google Scholar
• Litton JK, Scoggins M, Ramirez DL, et al. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer. 2017;3(1):49.
   PubMed Web of Science ®Google Scholar
• Litton JK, Scoggins ME, Hess KR, et al., Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020; 38(5): 388–394.
   PubMed Web of Science ®Google Scholar
• Garufi G, Palazzo A, Paris I, et al. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors. Expert Opin Pharmacother. 2020;21(6):687–699.
   PubMed Web of Science ®Google Scholar
• Balmana J, Tryfonidis K, Audeh W, et al. Abstract OT1-03-05: A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician’s choice in previously- treated, HER2 negative, germline BRCA mutation-positive breast cancer patients. An EORTC-BIG intergroup study (BRAVO study). Cancer Res. 2016;76(4 Supplement):OT1-03-05-OT01-03–05.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Olopade OI, DeMichele A, et al. Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016;375(1):23–34.
   PubMed Web of Science ®Google Scholar
• Loibl S, O’Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19(4):497–509.
   PubMed Web of Science ®Google Scholar
• Pilie PG, Tang C, Mills GB, et al. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16(2):81–104.
   PubMed Web of Science ®Google Scholar
• Liu X, Kantarjian H, Plunkett W. Sapacitabine for cancer. Expert Opin Investig Drugs. 2012;21(4):541–555.
   PubMed Web of Science ®Google Scholar
• Vikas P, Borcherding N, Chennamadhavuni A, et al. Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors. Front Oncol. 2020;10:570.
   PubMed Web of Science ®Google Scholar
• Jiao S, Xia W, Yamaguchi H, et al. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 2017;23(14):3711–3720.
   PubMed Web of Science ®Google Scholar
• Kumar A, Fernandez-Capetillo O, Carrera AC. Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair. Proc Natl Acad Sci U S A. 2010;107(16):7491–7496.
   PubMed Web of Science ®Google Scholar
• Juvekar A, Burga LN, Hu H, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2012;2(11):1048–1063.
   PubMed Web of Science ®Google Scholar
• Ibrahim YH, García-García C, Serra V, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012;2(11):1036–1047.
   PubMed Web of Science ®Google Scholar
• Lallo A, Frese KK, Morrow CJ, et al. The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer. Clin Cancer Res. 2018;24(20):5153–5164.
   PubMed Web of Science ®Google Scholar
• Kim H, George E, Ragland R, et al. Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models. Clin Cancer Res. 2017;23(12):3097–3108.
   PubMed Web of Science ®Google Scholar
• Yazinski SA, Comaills V, Buisson R, et al. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev. 2017;31(3):318–332.
   PubMed Web of Science ®Google Scholar
• Vena F, Jia R, Esfandiari A, et al. MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models. Oncotarget. 2018;9(14):11592–11603.
   PubMedGoogle Scholar
• Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019;380(8):741–751.
   PubMed Web of Science ®Google Scholar
• Karakashev S, Zhu H, Yokoyama Y, et al. BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer. Cell Rep. 2017;21(12):3398–3405.
   PubMed Web of Science ®Google Scholar
• Maslov AY, Lee M, Gundry M, et al. 5-aza-2ʹ-deoxycytidine-induced genome rearrangements are mediated by DNMT1. Oncogene. 2012;31(50):5172–5179.
   PubMed Web of Science ®Google Scholar
• Orta ML, Höglund A, Calderón-Montaño JM, et al. The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2ʹ-deoxycytidine lesions. Nucleic Acids Res. 2014;42(14):9108–9120.
   PubMed Web of Science ®Google Scholar
• Emberley ED, Bennett M, Chen J, et al. Abstract 3509: the glutaminase inhibitor CB-839 synergizes with CDK4/6 and PARP inhibitors in pre-clinical tumor models. Cancer Res. 2018;78(13 Supplement):3509.
   Web of Science ®Google Scholar
• Kirova YM, Loirat D, Berger F, et al. Radioparp: A phase I of olaparib with radiation therapy (RT) in patients with inflammatory, locoregionally advanced or metastatic triple-negative breast cancer (TNBC) or patient with operated TNBC with residual disease—Preliminary results. J Clin Oncol. 2020;38(15_suppl):571.
   Web of Science ®Google Scholar